INT21979

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1990
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 52
Total Number 53
Disease Relevance 24.65
Pain Relevance 12.55

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (EDN1) extracellular region (EDN1) cell-cell signaling (EDN1)
cytoplasm (EDN1)
Anatomy Link Frequency
plasma 7
coronary sinus 2
optic nerve 2
blood 2
myocardium 1
EDN1 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 202 100.00 Very High Very High Very High
tetrodotoxin 13 100.00 Very High Very High Very High
noradrenaline 4 100.00 Very High Very High Very High
orphanin 7 99.84 Very High Very High Very High
corticosteroid 24 99.80 Very High Very High Very High
fibrosis 198 99.42 Very High Very High Very High
Kinase C 12 99.30 Very High Very High Very High
Catecholamine 7 99.16 Very High Very High Very High
qutenza 60 98.56 Very High Very High Very High
Dismenorea 4 97.80 Very High Very High Very High
Disease Link Frequency Relevance Heat
Blister 46 100.00 Very High Very High Very High
Adhesions 5 100.00 Very High Very High Very High
Increased Venous Pressure Under Development 207 99.96 Very High Very High Very High
Sarcoidosis 584 99.74 Very High Very High Very High
Systemic Sclerosis 44 99.68 Very High Very High Very High
Natriuresis 5 99.64 Very High Very High Very High
Pulmonary Fibrosis 155 99.42 Very High Very High Very High
Hypertension 304 99.04 Very High Very High Very High
Disease 239 99.00 Very High Very High Very High
Diabetes Mellitus 78 98.64 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The amount of ET-1 generated from exogenously applied big ET-1 was markedly decreased by phosphoramidon in a concentration-dependent manner.
Negative_regulation (decreased) of ET-1
1) Confidence 0.58 Published 1995 Journal Biol. Pharm. Bull. Section Abstract Doc Link 7550091 Disease Relevance 0 Pain Relevance 0
First, our study demonstrated a nearly twofold decrease in ET-1 level (41%) compared with those observed (23%) in WebbÂ’s study.
Negative_regulation (decrease) of ET-1
2) Confidence 0.57 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2515431 Disease Relevance 0.13 Pain Relevance 0.04
The above vasoactive coronary properties of estrogen may be mediated via promotion of the release or action of potentially beneficial substances, such as nitric oxide (Gueta et al 1997; Rosano et al 1997; Best et al 1998) or via reduction of the release or action of potentially adverse mediators such as ET-1 (Jiang et al 1992; Lerman et al 1995; Lamping et al 1996; Sudhir et al 1996, 1997; Webb et al 2000).
Negative_regulation (reduction) of ET-1
3) Confidence 0.57 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2515431 Disease Relevance 0.09 Pain Relevance 0
-estradiol administration into the coronary circulation decreases coronary blood ET-1 level (Webb et al 2000).
Negative_regulation (decreases) of ET-1 in blood
4) Confidence 0.57 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2515431 Disease Relevance 0.14 Pain Relevance 0
The above mentioned estrogen-induced decrease in plasma ET-1 levels may possibly explain some of the acute anti-ischemic effects of estrogen.
Negative_regulation (decrease) of ET-1 in plasma
5) Confidence 0.57 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2515431 Disease Relevance 0.15 Pain Relevance 0.04
Prolonged exposure of the cells to IL-1beta led to a decrease in prepro-ET-1 and ET-3 mRNA correlated with a decrease in immunoreactive ET-1 and ET-3 levels in the culture medium.
Negative_regulation (decrease) of ET-1
6) Confidence 0.55 Published 2005 Journal Endocrinology Section Abstract Doc Link 16109787 Disease Relevance 0.18 Pain Relevance 0.18
It is unclear what the effect of disuse on the production of ET-1 and NO could be, but the plasma NOx concentration in healthy young humans significantly increases after exercise, with a significant decrease of ET-1 [41].
Negative_regulation (decrease) of ET-1 in plasma
7) Confidence 0.51 Published 2006 Journal BMC Musculoskelet Disord Section Body Doc Link PMC1693561 Disease Relevance 0.77 Pain Relevance 0.53
The greater reduction in ET-1 levels was accompanied by both less constriction of the artery and greater increase in CBF at the peak of AP in this setting.
Negative_regulation (reduction) of ET-1 in artery
8) Confidence 0.50 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2515431 Disease Relevance 0.16 Pain Relevance 0
Prolonged exposure of the cells to IL-1beta led to a decrease in prepro-ET-1 and ET-3 mRNA correlated with a decrease in immunoreactive ET-1 and ET-3 levels in the culture medium.
Negative_regulation (decrease) of prepro-ET-1
9) Confidence 0.48 Published 2005 Journal Endocrinology Section Abstract Doc Link 16109787 Disease Relevance 0.17 Pain Relevance 0.18
Moreover, in the presence of an ET-1 inhibitor, fibroblast proliferation was blocked.
Negative_regulation (inhibitor) of ET-1 in fibroblast
10) Confidence 0.46 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2072890 Disease Relevance 1.13 Pain Relevance 0.10
This raises intriguing questions about the clinical significance of ET-1 in sarcoidosis and whether blockade of ET-1 is a rational approach to therapy.
Spec (whether) Negative_regulation (blockade) of ET-1 associated with sarcoidosis
11) Confidence 0.46 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2072890 Disease Relevance 0.99 Pain Relevance 0.11
Pretreatment with naloxone hydrochloride enhanced (p < 0.01) SBP, heart rate, noradrenaline, cortisol, and endothelin-1 levels, and reduced (p < 0.01) ANF in low responders in response to MAT, whereas it decreased (p < 0.01) hemodynamic parameters, noradrenaline, and endothelin-1 in high responders.
Negative_regulation (decreased) of endothelin-1 in heart associated with noradrenaline and narcan
12) Confidence 0.45 Published 1997 Journal Peptides Section Abstract Doc Link 9149287 Disease Relevance 0.16 Pain Relevance 0.44
Endothelin receptor antagonists inhibit endothelin in human skin microcirculation.
Negative_regulation (inhibit) of endothelin in skin associated with antagonist
13) Confidence 0.45 Published 1994 Journal Hypertension Section Title Doc Link 8175165 Disease Relevance 0.23 Pain Relevance 0.24
We found that treatment of myometrial cell lattices with an inhibitory peptide specific for PKC zeta or with an antisense against PKC zeta resulted in a significant loss of ET-1-induced contraction.
Negative_regulation (s of) of ET-1-induced associated with kinase c
14) Confidence 0.43 Published 2003 Journal Am. J. Physiol., Cell Physiol. Section Abstract Doc Link 12748064 Disease Relevance 0.07 Pain Relevance 0.46
Transient raise of endothelin-1 plasma level and reduction of ocular blood flow in a patient with optic neuritis.
Negative_regulation (raise) of endothelin-1 in optic associated with optic neuritis and neuritis
15) Confidence 0.43 Published 2003 Journal Ophthalmologica Section Title Doc Link 14573982 Disease Relevance 0.10 Pain Relevance 0.19
Thus we can suggest that the degree of vasomotor response may be determined, at least partially, by the degree of decrease in ET-1 level.
Negative_regulation (decrease) of ET-1
16) Confidence 0.42 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2515431 Disease Relevance 0.14 Pain Relevance 0.04
The endothelin-1 (ET-1) levels in the coronary sinus were significantly reduced after estrogen infusion, which was negatively correlated with the degree of coronary artery constriction (r = ?
Negative_regulation (reduced) of ET-1 in coronary sinus
17) Confidence 0.42 Published 2008 Journal Vascular Health and Risk Management Section Abstract Doc Link PMC2515431 Disease Relevance 0.14 Pain Relevance 0
The endothelin-1 (ET-1) levels in the coronary sinus were significantly reduced after estrogen infusion, which was negatively correlated with the degree of coronary artery constriction (r = ?
Negative_regulation (reduced) of endothelin-1 in coronary sinus
18) Confidence 0.42 Published 2008 Journal Vascular Health and Risk Management Section Abstract Doc Link PMC2515431 Disease Relevance 0.14 Pain Relevance 0
Carolyn Webb and colleagues (2000) reported no change in coronary vasomotor or flow responses associated with a decrease in ET-1 levels in estradiol alone.
Negative_regulation (decrease) of ET-1
19) Confidence 0.42 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2515431 Disease Relevance 0.09 Pain Relevance 0.03
Furthermore, our study is unique because we showed for the first time that a relationship exists between the estrogen-induced reduction in coronary sinus ET-1 levels and the degree of both the constriction of the coronary artery and the increase in CBF at the peak of AP in postmenopausal women without atherosclerotic coronary arteries.
Negative_regulation (reduction) of ET-1 in coronary artery associated with atherosclerosis
20) Confidence 0.42 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2515431 Disease Relevance 0.16 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox